TaqMan real time PCR for the Detection of the Gilbert’s Syndrome Markers UGT1A1*28; UGT1A1*36 and UGT1A1*37

被引:0
作者
Valentina Daprà
Carla Alliaudi
Ilaria Galliano
Maddalena Dini
Giada Lo Curcio
Cristina Calvi
Marialaura Archetti
Martina Gavatorta
Massimiliano Bergallo
机构
[1] University of Turin,Department of Public Health and Pediatrics, School of Medicine
[2] BioMole srl.,undefined
来源
Molecular Biology Reports | 2021年 / 48卷
关键词
Real time PCR; Gilbert's syndrome; Allelic discrimination; UGT1A1*28; UGT1A1*36; UGT1A1*37; Pharmacogenetics;
D O I
暂无
中图分类号
学科分类号
摘要
Gilbert’s syndrome is characterized by mild unconjugated hyperbilirubinemia. The key of this disease is a diminished activity of UDP-glucuronosyltransferase 1A1 (UGT1A1). TA insertion into the TATA box promoter region of the UGT1A1 gene on chromosome 2 is the genetic basis of Gilbert’s syndrome (UGT1A1*28). An extra TA insert leads to eight (TA)8 repeats (UGT1A1*37) resulting in a further reduction of glucuronidation activity. A variant lacking one TA repeat (TA)5 (UGT1A1*36) has been identified. (TA)8 repeats (UGT1A1*37) and (TA)5 (UGT1A1*36) have been detected in Africans (frequency up to 0.07 and 0.08 respectively). We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR on 7500 and cfx96 Real-Time PCR System. We present a real time PCR method for genotyping the UGT1A1 (TA)n polymorphism (UGT1A1*28, UGT1A1*36, UGT1A1*37) using Taqman PCR. About clinical validation, all 53 samples collected from patients referred for suspected Gilbert’s syndrome were analyzed. We found 21 on the 53 patients (39.6%) were homozygotes (UGT1A1-TATA (TA)6) and referred as wild-type, 13 on the 53 patients (24.5%) were homozygotes (UGT1A1-TATA (TA)7) and referred as mutated, 1 on the 53 patients (1.9%) were homozygotes (UGT1A1-TATA (TA)8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)7/8) and referred as mutated, 1 on the 53 patients (1.9%) were heterozygotes (UGT1A1-TATA (TA)5/6) and referred as mutated, and 16 on the 53 patients (30.2%) were heterozygotes (UGT1A1-TATA (TA)6/7). None were homozygotes UGT1A1-TATA (TA)5, homozygotes UGT1A1-TATA (TA)8, or heterozygotes with (TA)5 or (TA)8 alleles. The newly described technique represents a valid alternative method to sequencing, mainly due to its rapidity, easiness, and minor costs.
引用
收藏
页码:4953 / 4959
页数:6
相关论文
共 50 条
[31]   Irinotecan pharmacogenetics in Japanese cancer patients:: Roles of UGT1A1*6 and*28 [J].
Sai, Kirnie ;
Sawada, Jun-Ichi ;
Minami, Hironobu .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2008, 128 (04) :575-584
[32]   Dual deficiency of DPD and UGT1A1 in a case of colon cancer [J].
Rawlley, Bharat ;
Diab, Osama ;
Al-Rajabi, Raed ;
Carroll, Erin ;
Melancon, Tina ;
Kasi, Anup .
PHARMACOGENOMICS, 2020, 21 (18) :1265-1269
[33]   Distribution of selected gene polymorphisms of UGT1A1 in a Saudi population [J].
Alkharfy, Khalid M. ;
Alghamdi, Amal M. ;
Bagulb, Khawla M. ;
Al-Jenoobi, Fahad I. ;
Al-Mohizea, Abdullah M. ;
Al-Muhsen, Saleh ;
Halwani, Rabih ;
Parvez, Mohammad K. ;
Al-Dosari, Mohammed S. .
ARCHIVES OF MEDICAL SCIENCE, 2013, 9 (04) :731-738
[34]   Performance of In Silico Tools for the Evaluation of UGT1A1 Missense Variants [J].
Rodrigues, Carina ;
Santos-Silva, Alice ;
Costa, Elisio ;
Bronze-da-Rocha, Elsa .
HUMAN MUTATION, 2015, 36 (12) :1215-1225
[35]   Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk [J].
McGrath, Monica ;
Lepine, Johanie ;
Lee, I-Min ;
Villeneuve, Lyne ;
Buring, Julie ;
Guillemette, Chantal ;
De Vivo, Immaculata .
PHARMACOGENETICS AND GENOMICS, 2009, 19 (03) :239-243
[36]   Predicting the risk of sporadic elevated bilirubin levels and diagnosing Gilbert's syndrome by genotyping UGT1A1*28 promoter polymorphism [J].
Rauchschwalbe, SK ;
Zühlsdorf, MT ;
Schühly, U ;
Kuhlmann, J .
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2002, 40 (06) :233-240
[37]   Rapid UGT1A1 (TA)n genotyping by high resolution melting curve analysis for Gilbert's syndrome diagnosis [J].
Minucci, Angelo ;
Concolino, Paola ;
Giardina, Bruno ;
Zuppi, Cecilia ;
Capoluongo, Ettore .
CLINICA CHIMICA ACTA, 2010, 411 (3-4) :246-249
[38]   Development of a new DHPLC assay for genotyping UGT1A1(TA)n polymorphism associated with Gilbert's syndrome [J].
Mlakar, Simona Jurkovic ;
Ostanek, Barbara .
BIOCHEMIA MEDICA, 2011, 21 (02) :167-173
[39]   Non tumoral hyperserotoninaemia responsive to octreotide due to dual polymorphism in UGT1A1 and UGT1A6 [J].
Anna Maladaki ;
Maria P. Yavropoulou ;
Kalliopi Kotsa ;
Theoni Tranga ;
Stelios Ventis ;
John G. Yovos .
Hormones, 2012, 11 :104-108
[40]   Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab [J].
Lee, Janet S. ;
Wang, Jianmei ;
Martin, Mitchell ;
Germer, Soren ;
Kenwright, Andrew ;
Benayed, Ryma ;
Spleiss, Olivia ;
Platt, Adam ;
Pilson, Robert ;
Hemmings, Andrew ;
Weinblatt, Michael E. ;
Kaplowitz, Neil ;
Krasnow, Joel .
PHARMACOGENETICS AND GENOMICS, 2011, 21 (07) :365-374